Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Kazuoki Kondo"'
Autor:
Hitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, Atsuo Maemoto, Takayuki Matsumoto, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, Kazuoki Kondo, Toshifumi Hibi
Publikováno v:
PLoS ONE, Vol 17, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/19fa0a9f69874c2db3a458026de01630
Autor:
Hitoshi Tajiri, Katsuhiro Arai, Seiichi Kagimoto, Reiko Kunisaki, Nobuyuki Hida, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, Kazuoki Kondo, Toshifumi Hibi
Publikováno v:
BMC Pediatrics, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Pediatric ulcerative colitis (UC) is typically more extensive and has a more active disease course than adult UC, and requires early treatment augmentation to achieve and maintain disease remission. The present study aimed to inve
Externí odkaz:
https://doaj.org/article/fef5f15419144eb68e03c0bd5d6c6e42
Autor:
Hitoshi Tajiri, Satoshi Motoya, Fukunori Kinjo, Atsuo Maemoto, Takayuki Matsumoto, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, Kazuoki Kondo, Toshifumi Hibi
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201956 (2018)
OBJECTIVES:The prevalence of pediatric Crohn's disease (CD) is increasing in Japan and other countries, and many patients are unresponsive to or do not tolerate current treatment options. This study aimed to investigate the efficacy, safety, and phar
Externí odkaz:
https://doaj.org/article/54495b6afda746d38c11181a383b9c27
Autor:
Jun Horiguchi, Koichiro Watanabe, Kazuoki Kondo, Atsushi Iwatake, Hajime Sakamoto, Yutaka Susuta, Hideaki Masui, Yumi Watanabe
Publikováno v:
Psychiatry and Clinical Neurosciences. 76:560-569
Valbenazine is approved in the US for treatment of tardive dyskinesia (TD); however, efficacy/safety data in Asian populations are lacking. We assessed the efficacy/safety of valbenazine in Japanese patients.This phase II/III, multicenter, randomized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed902453f0e3f73465f35aa4c9ba41d
https://doi.org/10.1111/pcn.13455
https://doi.org/10.1111/pcn.13455
Autor:
Kazuoki Kondo, Yukiko Nishimura, Yuichiro Kato, Yoshinobu Nakamaru, Hidetoshi Shimizu, Hideaki Matsuda, Yoichi Shiide, Makoto Akimoto, Munetomo Matsuda
Publikováno v:
Clinical Pharmacology in Drug Development
Intravenous (IV) edaravone is approved as an amyotrophic lateral sclerosis (ALS) treatment. Because IV administration places a burden on patients, development of orally administered ALS treatments is needed. Therefore, 2 phase 1 studies of oral formu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3e7b2ae163a134ef269f3c843a032d8
http://europepmc.org/articles/PMC8518673
http://europepmc.org/articles/PMC8518673
Autor:
Genki Kaneko, Hiroki Matsuda, Yoshimasa Kokado, Yutaka Kawaguchi, Kiichiro Ueta, Masaomi Nangaku, Kazuoki Kondo, Yasuhiro Komatsu
Publikováno v:
Nephrology Dialysis Transplantation
Background Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. Methods The efficacy and safety of vadadustat, compared with darbepoetin alfa, was determined in a Phase 3 double-blind study in Ja
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfacb87647ab37d09f931d2c6d6e9da5
https://doi.org/10.1093/ndt/gfab055
https://doi.org/10.1093/ndt/gfab055
Publikováno v:
Clinical Therapeutics. 42:1699-1714
Purpose The goal of this study was to compare edaravone pharmacokinetic (PK) variables and tolerability after a single intravenous (IV) infusion of 30 mg over 60 min in subjects with mild renal impairment (estimated glomerular filtration rate 60–89
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::392c20c538f17e9061b1eb1fbeab50cc
https://doi.org/10.1016/j.clinthera.2020.06.020
https://doi.org/10.1016/j.clinthera.2020.06.020
Autor:
Hidetoshi Shimizu, Kaori Yoshida, Makoto Akimoto, Tomoko Natori, Shinsuke Inoue, Mai Endo, Kazuoki Kondo, Masae Kakubari, Yoshinobu Nakamaru
Publikováno v:
Clinical Pharmacology in Drug Development
This randomized, single‐blind, 3‐way crossover study assessed the effect of edaravone on QT interval, including an exposure‐response analysis. Twenty‐seven healthy Japanese male volunteers, aged 20 to 49 years, were randomly assigned to recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1a6e283b824a7c5c6d89a23f04c3041
https://doi.org/10.1002/cpdd.814
https://doi.org/10.1002/cpdd.814
Autor:
Kazuoki Kondo, Yasuhiro Komatsu, Genki Kaneko, Yoshimasa Kokado, Yutaka Kawaguchi, Kiichiro Ueta, Masaomi Nangaku, Tsubasa Tandai
Publikováno v:
J Am Soc Nephrol
Background Standard care for treating anemia in patients with CKD includes use of erythropoiesis-stimulating agents, which sometimes involves increased risks of cardiovascular morbidity and mortality. Previous studies in patients with anemia and nond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::348eaabd405fdbb475ed2a3bf1e081be
https://europepmc.org/articles/PMC8425651/
https://europepmc.org/articles/PMC8425651/
Autor:
Souichirou Takabe, Masaomi Nangaku, Kazuoki Kondo, Yasuhiro Komatsu, Yutaka Kawaguchi, Tsubasa Tandai, Kiichiro Ueta
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 26(1)
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in Japan for the treatment of anemia in patients with chronic kidney disease (CKD). This phase 3, open-label, single-arm study evaluated the efficacy and safety of v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddecec601a7d5c4178c1068cc98950f8
https://pubmed.ncbi.nlm.nih.gov/34115437
https://pubmed.ncbi.nlm.nih.gov/34115437